NCT05057546 is a Phase 4 clinical trial of GnRH antagonist in Menopause, sponsored by University of Colorado, Denver.

Who is sponsoring NCT05057546?

NCT05057546 is sponsored by University of Colorado, Denver.

What drugs are being tested in NCT05057546?

Interventions in NCT05057546: GnRH antagonist.

What condition does NCT05057546 study?

NCT05057546 studies Menopause, Estrogen Deficiency, Women, Aging.

Is NCT05057546 still recruiting?

NCT05057546 is currently active, enrolled. Last updated 27 March 2025.

Last reviewed 2025-03-27 · How we verify

NCT05057546

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Ovarian Hormone Regulation of Central and Cerebrovascular Hemodynamics (NoMEN Study)

Active, enrolled Phase 4 Last updated 27 March 2025

What this trial tests

Phase 4 trial testing GnRH antagonist in Menopause in 55 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

22 November 2021

Primary endpoint
18 September 2024

28 July 2025

Quick facts

Lead sponsor	University of Colorado, Denver
Phase	Phase 4
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	basic science
Enrollment	55
Start date	22 November 2021
Primary completion	18 September 2024
Estimated completion	28 July 2025
Sites	1 location across United States

Drugs / interventions tested

GnRH antagonist — full drug profile →

Conditions studied

Menopause — all drugs for Menopause →
Estrogen Deficiency — all drugs for Estrogen Deficiency →
Women — all drugs for Women →
Aging — all drugs for Aging →

Sponsor

University of Colorado, Denver

Who can join

Adults 18 to 65, female only, with Menopause or Estrogen Deficiency. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study will evaluate changes in blood vessels around the heart (e.g., aorta and carotid arteries) and in the brain with the loss of female sex hormones (e.g., estrogen) during the menopause transition. The menopause transition is associated with declines in blood vessel function and increased risk for cardiovascular disease and Alzheimer's disease. Increasing evidence supports an early role for declines in blood vessel function and future development of Alzheimer's disease in aging men and women. This study will learn about the effects of changes in female sex hormones, such as estrogen, during the menopause transition on blood vessel around the heart and in the brain in women.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of GnRH antagonist

Trials testing the same drug.

NCT05326087 — Comparison of the Euploid Rate of Blastocyst Between PPOS and GnRH Antagonist Protocol in Women With PCOS Undergoing PGT · Phase 3 · not yet recruiting
NCT07212712 — The Role of Estrogen and Testosterone in Determining Brain Blood Flow and Metabolic Regulation in Humans · NA · not yet recruiting
NCT06396390 — Comparison of Progestin Primed Ovarian Stimulation (PPOS) vs.GnRH Antagonist Methods on IVF Outcomes · Phase 4 · not yet recruiting
NCT05759871 — Ovarian Stimulation With FSH Alone Versus FSH Plus GnRH Antagonist in an Oocyte Donor/Recipient Programme · Phase 1, PHASE2 · unknown
NCT05447208 — Effect of GH on the Blastocyst Euploid Rate in AMA Patients · Phase 3 · recruiting

Other recruiting trials for Menopause

Currently open trials in the same condition.

NCT07472881 — Multi-Acupoint Laser Therapy for Body Shape and Composition in Obese Menopausal Women · NA · recruiting
NCT07135232 — The Effects of Resistance Training and a Plant-Based Supplement on Perimenopausal Symptoms and Muscle Health. · NA · recruiting
NCT06975111 — Focusing on the Menopausal Transition to Improve Mid-Life Women's Health · Phase 2, PHASE3 · recruiting
NCT07393672 — Effects of Hemp-Derived Cannabinoids on Menopause Symptoms · Phase 2 · recruiting
NCT07412093 — The Effect of Progressive Relaxation Exercises and Planned Education on Menopausal Symptoms, Perceived Stress, and Anxie · NA · active not recruiting

Other University of Colorado, Denver trials

Trials by the same sponsor.

NCT07292285 — The Surveillance Nonoperative Watch & Wait (SNOWW) Rectal Cancer Trial. · not yet recruiting
NCT07021937 — Brain Plasticity and GLP-1 Receptor Agonist Treatment for Obesity · Phase 3 · not yet recruiting
NCT07453732 — Banana Leaves as a Wound Dressing for Partial Thickness Second Degree Burns in Adult Patients. · NA · not yet recruiting
NCT07038278 — 5-AminoLevulinic Acid Aided Resection Margins in Sarcoma · EARLY_PHASE1 · not yet recruiting
NCT07279558 — Cannabidiol and Alcohol Use Disorder Phenotypes · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05057546 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Colorado, Denver
Last refreshed: 27 March 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05057546.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing